Feb 23, 2021
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
Feb 22, 2021
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
Feb 08, 2021
Biohaven Provides Update On ESG Practices
Jan 25, 2021
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
Jan 18, 2021
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
Jan 18, 2021
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Jan 07, 2021
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
Jan 05, 2021
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
Dec 16, 2020
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
Dec 02, 2020
Biohaven's Nurtec(TM) ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
Nov 16, 2020
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
Nov 11, 2020
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
Nov 09, 2020
Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments
Oct 30, 2020
Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020
Oct 14, 2020
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC(TM) ODT For The Preventive Treatment Of Migraine
Sep 28, 2020
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Sep 10, 2020
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
Aug 10, 2020
Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments
Aug 07, 2020
Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street
Aug 03, 2020
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital